North East patients are among the first in the UK to trial Lutetium (177Lu) rhPSMA-10.1, a new targeted treatment for advanced prostate cancer resistant to hormone therapy.
Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who ...
The MarketWatch News Department was not involved in the creation of this content. St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC ...
News Medical on MSN
Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can ...
Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme Dr Kenrick Ng, Medical Oncology Consultant, St Bartholomew's Hospital, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results